This information was published on 2025-11-28T00:09:06 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2596602 |
| (220) |
21 Oct 2025
|
| (300) |
US, 27 Jun 2025, 99256173
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes. |
| (540) | AHWISPO |
| (550) | Word |
| (730) |
Bristol-Myers Squibb Company
|
| (750) |
Spruson & Ferguson
|
Find out more about publications on the About page.